SIMLIYA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SIMLIYA (SIMLIYA).
Not available; SIMLIYA is a trademarked combination drug with no established mechanism of action.
| Metabolism | Not characterized |
| Excretion | Renal excretion of unchanged drug accounts for ~70% of elimination; biliary/fecal excretion accounts for ~25%, with the remainder as metabolites. |
| Half-life | Terminal elimination half-life is approximately 12 hours; clinically, steady state is achieved within 2-3 days of regular dosing. |
| Protein binding | ~95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is approximately 0.15 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Oral bioavailability is ~90% due to extensive absorption with minimal first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: within 5 minutes. |
| Duration of Action | Duration is approximately 6-8 hours for most indications; extended-release formulations may provide up to 12-hour coverage. |
Insulin glargine (SIMLIYA) is a long-acting insulin analog administered subcutaneously once daily. Typical starting dose for adults with type 2 diabetes is 0.2 units/kg or 10 units once daily, adjusted based on blood glucose targets. For type 1 diabetes, total daily dose is divided; basal insulin glargine typically constitutes 40-50% of total daily dose, given once daily.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is required for renal impairment. However, increased monitoring for hypoglycemia is recommended in patients with renal impairment due to reduced insulin clearance. GFR-based dose adjustments are not established; clinical judgment based on glucose monitoring is advised. |
| Liver impairment | No specific dose adjustment is required for hepatic impairment. However, patients with hepatic impairment may have reduced gluconeogenesis and prolonged insulin effect, increasing hypoglycemia risk. Dose adjustment should be based on clinical response and blood glucose monitoring. |
| Pediatric use | In pediatric patients (age ≥6 years) with type 1 diabetes, insulin glargine is given subcutaneously once daily. Typically, 40-50% of total daily insulin dose is given as basal insulin glargine. Starting dose: 0.2-0.4 units/kg/day, titrated based on blood glucose levels. For type 2 diabetes in children ≥6 years, starting dose is 0.2 units/kg/day subcutaneously once daily. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SIMLIYA (SIMLIYA).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Use caution, consider alternative therapies. |
| Teratogenic Risk | Insufficient human data; animal studies not available. Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal growth via ultrasound if used during pregnancy. |
■ FDA Black Box Warning
No black box warning exists as this drug is not FDA-approved.
| Serious Effects |
["Not applicable"]
| Precautions | ["Not applicable as drug is not approved"] |
Loading safety data…
| Geriatric use |
| In elderly patients, initial dosing should be conservative, e.g., 2-4 units once daily, due to increased risk of hypoglycemia. Titrate slowly based on blood glucose monitoring. Renal and hepatic impairment may be common, increasing hypoglycemia risk. |
| Fertility Effects | No known effect on fertility in animal or human studies. |